Bio Business

» FDA, tuberculosis, biobusiness and cancer

Most Recent

image: Accessing Drugs for Medical Aid-in-Dying

Accessing Drugs for Medical Aid-in-Dying

By | August 17, 2017

A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

0 Comments

image: Learning from Iceland’s Model for Genetic Research

Learning from Iceland’s Model for Genetic Research

By | June 1, 2017

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

1 Comment

image: Making CAR T-Cell Therapy Safer

Making CAR T-Cell Therapy Safer

By | April 1, 2017

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

0 Comments

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Banking on Blood Tests

Banking on Blood Tests

By | April 1, 2016

How close are liquid biopsies to replacing current diagnostics?

1 Comment

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

0 Comments

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

4 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

2 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

Popular Now

  1. Optimism for Key Deer After Hurricane Irma
  2. Do Microbes Trigger Alzheimer’s Disease?
  3. Decoding the Tripping Brain
  4. Tattoo Ink Nanoparticles Persist in Lymph Nodes
    The Nutshell Tattoo Ink Nanoparticles Persist in Lymph Nodes

    Analysis of the bodies of deceased individuals can’t determine what effect these tattoo remnants have on lymph function, but researchers suggest dirty needles aren’t the only risk of the age-old practice.

AAAS